Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Gynecologic 1

Conditions

Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Uterine Hemorrhage 1Sarcoma 1Prostatic Neoplasms 1Leiomyoma 1Endometrial Stromal Tumors 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1

Interventions

Trastuzumab 4liposomal doxorubicin 2Interleukin-12 Subunit p35 2Interleukin-12 2Early Intervention, Educational 2Docetaxel 2veliparib 1tipifarnib 1temsirolimus 1sargramostim 1ixabepilone 1entinostat 1cediranib 1Watchful Waiting 1Vorinostat 1Vinorelbine 1Therapeutics 1Taxes 1TIC10 compound 1Standard of Care 1Sirolimus 1Radiotherapy 1Pyridoxine 1Psychiatric Rehabilitation 1Propranolol 1Practice Guidelines as Topic 1Physical Therapy Modalities 1Pemetrexed 1Paclitaxel 1Mifepristone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms, Male × Mifepristone × Gynecologic × Clear all
NCT02046421 2018-09-11

Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

University of Chicago

Phase 1 Completed
31 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡